VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C

被引：0
|
作者：
Hammond, E. [1 ]
Lucas, A. [1 ]
Lucas, M. [1 ]
Phillips, E. [1 ,4 ,5 ]
Gaudieri, S. [2 ,3 ,6 ,7 ]
机构：
[1] Murdoch Univ, Inst Immunol & Infect Dis, Ctr Clin Immunol & Biomed Stat, Murdoch, WA 6150, Australia
[2] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
[4] Univ Western Australia, Sch Pathol, Nedlands, WA 6009, Australia
[5] Univ Western Australia, Lab Med & Biomed Biomol & Chem Sci, Nedlands, WA 6009, Australia
[6] Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia
[7] Univ Western Australia, Ctr Forens Sci, Nedlands, WA 6009, Australia
来源：
DRUGS OF THE FUTURE | 2010年 / 35卷 / 10期
关键词：
MK-7009; CHRONIC HEPATITIS-C; VIRUS NS3/4A PROTEASE; PEGINTERFERON ALPHA-2A; RIBAVIRIN THERAPY; RESISTANCE; INHIBITORS; TELAPREVIR; NOMENCLATURE; ASSOCIATION; MANAGEMENT;
D O I：
10.1358/dof.2010.035.010.1527293
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protease inhibitors are among a number of new classes of direct-acting antivirals for hepatitis C which, when combined with conventional peginterferon alfa/ribavirin or with other classes of direct-acting antivirals, offer the potential to vastly improve disease outcomes for affected individuals. Early evaluations imply that a number of these agents are well tolerated and produce encouraging rapid declines in plasma viral load. Concerns relate to the rapid development of drug resistance, with resulting viral rebound. Vaniprevir (MK-7009) is a novel inhibitor of genotype 1 proteases with some potency against genotype 2 currently undergoing phase II trials.
引用
收藏
页码：803 / 813
页数：11
相关论文
共 50 条
  • [41] A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells
    Breiman, Adrien
    Vitour, Damien
    Vilasco, Myriam
    Ottone, Catherine
    Molina, Sonia
    Pichard, Lydiane
    Fournier, Chantal
    Delgrange, David
    Charneau, Pierre
    Duverlie, Gilles
    Wychowski, Czeslaw
    Maurel, Patrick
    Meurs, Eliane F.
    JOURNAL OF GENERAL VIROLOGY, 2006, 87 : 3587 - 3598
  • [42] Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Naggie, Susanna
    Patel, Keyur
    McHutchison, John
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) : 2063 - 2069
  • [43] Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease
    Duan, Maosheng
    Kazmierski, Wieslaw
    Crosby, Renae
    Gartland, Margaret
    Ji, Jinjing
    Tallant, Matt
    Wang, Amy
    Hamatake, Robert
    Wright, Lois
    Wu, Min
    Zhang, Yong-Kang
    Ding, Charles Z.
    Li, Xianfeng
    Liu, Yang
    Zhang, Suoming
    Zhou, Yasheen
    Plattner, Jacob J.
    Baker, Stephen J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (08) : 2993 - 2996
  • [44] Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease
    Skorenski, Marcin
    Pachota, Magdalena
    Pyrc, Krzysztof
    Sienczyk, Marcin
    Oleksyszyn, Jozef
    ANTIVIRAL RESEARCH, 2017, 144 : 286 - 298
  • [45] Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
    Chatel-Chaix, Laurent
    Baril, Martin
    Lamarre, Daniel
    VIRUSES-BASEL, 2010, 2 (08): : 1752 - 1765
  • [46] Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors
    Ozen, Aysegul
    Prachanronarong, Kristina
    Matthew, Ashley N.
    Soumana, Djade I.
    Schiffer, Celia A.
    CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 54 (01) : 11 - 26
  • [47] BI-201335 Treatment of Hepatitis C Virus Serine Protease NS3/Non-Structural Protein 4A (NS4A) Inhibitor
    Vachon, Marie-Louise
    DRUGS OF THE FUTURE, 2012, 37 (02) : 99 - 109
  • [48] The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
    Lahser, Frederick C.
    Bystol, Karin
    Curry, Stephanie
    McMonagle, Patricia
    Xia, Ellen
    Ingravallo, Paul
    Chase, Robert
    Liu, Rong
    Black, Todd
    Hazuda, Daria
    Howe, Anita Y. M.
    Asante-Appiah, Ernest
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 2954 - 2964
  • [49] PRECLINICAL CHARACTERIZATION OF NON-COVALENT HCV NS3/4A PROTEASE INHIBITOR BI 201335
    White, P. W.
    Llinas-Brunet, M.
    Amad, M.
    Bolger, G.
    Cordingley, M. G.
    Duan, J.
    Garneau, M.
    Lagace, L.
    Thibeault, D.
    Kukolj, G.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S302 - S302
  • [50] CHARACTERIZATION OF RESISTANT MUTANTS SELECTED IN VITRO BY THE HCV NS3/4A PROTEASE INHIBITOR BI 201335
    Kukolj, G.
    Bousquet, C.
    Dansereau, N.
    Do, F.
    Lagace, L.
    Llinas-Brunet, M.
    Marquis, M.
    Massariol, M. -J.
    Maurice, R.
    Spickler, C.
    Thibeault, D.
    Zhao, S.
    White, P. W.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S295 - S295
12345